Context Therapeutics Inc. (NASDAQ:CNTX) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Context Therapeutics Inc. (NASDAQ:CNTX) has earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $6.17.

Several brokerages recently weighed in on CNTX. Wall Street Zen downgraded shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th. Maxim Group reduced their target price on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, June 16th. Weiss Ratings cut shares of Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Lifesci Capital downgraded shares of Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Finally, Citigroup restated an “outperform” rating on shares of Context Therapeutics in a research note on Thursday, August 6th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CNTX. BlackRock Inc. purchased a new stake in shares of Context Therapeutics during the second quarter worth approximately $3,417,000. Octagon Capital Advisors LP acquired a new stake in Context Therapeutics in the first quarter valued at approximately $13,755,000. Blue Owl Capital Holdings LP acquired a new stake in Context Therapeutics in the second quarter valued at approximately $1,625,000. ADAR1 Capital Management LLC purchased a new position in Context Therapeutics in the second quarter worth approximately $416,000. Finally, Timothy G. Youngquist 2020 Irrevocable Trust purchased a new position in Context Therapeutics in the second quarter worth approximately $110,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Context Therapeutics Price Performance

Shares of NASDAQ:CNTX opened at $0.28 on Wednesday. The firm has a market capitalization of $25.27 million, a PE ratio of -0.57 and a beta of 1.71. The firm’s 50-day moving average is $0.40 and its two-hundred day moving average is $1.22. Context Therapeutics has a 1 year low of $0.27 and a 1 year high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.06). Analysts expect that Context Therapeutics will post -0.45 EPS for the current fiscal year.

About Context Therapeutics

Context Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing targeted treatments for solid tumors, with an emphasis on therapies designed to address cancers with limited treatment options. The company is headquartered in Philadelphia, Pennsylvania, and its activities are centered on the discovery and clinical development of oncology medicines.

Context’s lead program is CTIM-76, an investigational bispecific T-cell engager designed to bind Claudin 6 (CLDN6) on tumor cells and CD3 on T cells.